General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-01 | 2024-03 | -0.04 | -0.01 | 0.03 | 75.00% |
2024-02-29 | 2023-12 | -0.04 | N/A | N/A | N/A |
2023-11-01 | 2023-09 | -0.02 | N/A | N/A | N/A |
2023-08-02 | 2023-06 | -0.02 | 0.02 | 0.04 | 200.00% |
2023-05-03 | 2023-03 | -0.01 | 0.02 | 0.03 | 300.00% |
2023-03-01 | 2022-12 | 0.01 | 0.02 | 0.01 | 100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-19 | Goldman Sachs | Upgrade | Sell | Sell |
2023-07-18 | Northland Capital Markets | Upgrade | Market Perform | Market Perform |
2023-01-05 | Jefferies | Upgrade | Hold | Buy |
2022-10-18 | SVB Leerink | Upgrade | Market Perform | |
2022-05-23 | Goldman Sachs | Upgrade | Sell | |
2022-05-05 | JP Morgan | Downgrade | Neutral | Underweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-01-30 | BERG AARON D. | Officer | 633.26K | Conversion of Exercise of derivative security |
2024-01-21 | HOLT PATRICK | Chief Executive Officer | 314.43K | Purchase |
2022-07-28 | KALB MICHAEL WAYNE | Chief Financial Officer | 337.31K | Conversion of Exercise of derivative security |
2024-01-30 | KETCHUM STEVEN B | Officer | 658.72K | Conversion of Exercise of derivative security |
2022-08-18 | MARKS JASON M | Officer | 21.92K | Conversion of Exercise of derivative security |
2023-02-20 | MIKHAIL KARIM | Chief Executive Officer | 283.51K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Kynam Capital Management, LP | 12.00M | 14.28M | 12.15% |
2023-06-29 | Morgan Stanley | 11.28M | 13.42M | 11.41% |
2023-06-29 | Eversept Partners, LP | 10.50M | 12.50M | 10.63% |
2023-06-29 | Tang Capital Management, LLC | 7.10M | 8.45M | 7.19% |
2023-06-29 | SCP Investment, LP | 6.50M | 7.74M | 6.58% |
2023-06-29 | DG Capital Management, LLC | 5.47M | 6.51M | 5.54% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Northern Lights Fd Tr-13D Activist Fd | 3.81M | 4.53M | 3.85% |
2023-06-29 | Mutual Fund Ser Tr-AlphaCentric LifeSci Healthcare Fund | 585.00K | 696.15K | 0.59% |
2023-06-29 | Legg Mason Clearbridge Small Cap Value Fd | 531.07K | 631.97K | 0.54% |
2023-06-29 | Columbia Fds Var Ser Tr II-Columbia Var Port-Overseas Core Fd | 458.93K | 546.12K | 0.46% |
2023-05-30 | Columbia Fds Ser Tr-Columbia Overseas Value Fd | 315.88K | 369.58K | 0.32% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 214.39K | 250.83K | 0.22% |
Split | Date |
---|---|
0.1 : 1 | 2008-01-18 |
0.1 : 1 | 1998-10-19 |
So many people had spread BO rumors above the PT by experts. Now most longs just want to earn their loses back
FDA will approve for unlimited trigs
14.97 and was 13.07 AH last night. Not too bad for shorts and all the sellers
What if the FDA calls for one last trial. I am long but the FDA seems to have a huge vendetta with Amarin and this is a very real possibility.
Did anyone consider that FDA decided on a priority review to prove Amarin data false and stop the off label sale of Vascepa quickly?
Script numbers look really strong
Someone answer this.....why did the FDA wait so long to announce Adcom when it moved their own priority deadline of 9/28. Only reason I can come up with is pay back
Additional trials coming.
JT really should not speak publicly.
Customary for a break through drug to have an Adcom.....thank you professor JT.
They give priority review with a decision slated for 9/28 then wait until the very last minute to want an Adcom pushing the deadline off 2 months. I believe the FDA is screwing with Amarin and just might reject the label expansion. 78 percent of priority reviews get approved. Have a feeling Amarin is the other 22 percent
I wonder if somebody at Baker brothers prompted the FDA to invite an Adcom in order to get cheaper shares
If management had said all along that they were expecting in Adcom this would not have dropped as much
FDA approval between Sept 3rd and Sept 20th. Everyone will be back from vacation and volume will spike. Will not go much higher than $25pps. BO only thing which will make a difference in your lives
Low volume.......everyone is on vacation
This will spike again around $22-$23pps and then did again before FDA approval. Buy the dip
PLEASE NO FDA APPROVAL PRIOR TO LABOR DAY. Everyone is on vacation and volume will be low
FDA approval in Sept will make this move to maybe $23. This will be the last hurdle and then will sit until a BO
Robert Hill - absolutely not and they are not going to dump a unicorn drug for $25pps
Congrats to shorts. To short this at $23 my hats off to you. Big balls